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Vascular calcifications are very common in dialysis patients
and have been shown to be associated independently with
outcome. However, all of these studies used prevalent
patients on dialysis since many years. We investigated
vascular calcifications in an inception cohort of dialysis
patients and followed them for cardiovascular disease
outcomes during an average observation period of 66
months. One hundred and fifty-four Caucasian dialysis
patients were enrolled in one Austrian dialysis center.
Standardized plain radiographs from the pelvis and calves
were carried out in all patients at the start of dialysis therapy.
Vascular calcifications were assessed by a single radiologist.
At the start of renal replacement therapy, 67.5% of the
patients showed vascular calcifications. During follow-up,
29.9% of patients suffered a cardiovascular event. An additive
‘vascular risk score’, constructed from the presence of
vascular calcifications and/or previous cardiovascular events
before the start of dialysis treatment, showed the strongest
independent association with cardiovascular events in the
Cox regression model adjusted for various risk factors. The
presence of each of these two conditions was associated with
a hazard ratio of 2.03 (95% confidence interval 1.19–3.46) and
a hazard ratio twice as high if both conditions were present.
In summary, vascular calcifications on plain X-rays of pelvis
and calves are largely present in incident dialysis patients. A
history of a cardiovascular event in the predialysis period
together with vascular calcifications at the beginning of
dialysis therapy is a more powerful predictor of a
cardiovascular event than age, smoking, diabetes, or other
traditional risk factors.
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Evidence of vascular calcification is exceedingly more striking
in chronic renal failure than in the general population.1,2 A
combination of two major pathologies is responsible for this
phenomenon. Firstly, intimal calcification occurring in
atherosclerotic lesions,3–5 and secondly, medial calcification,
well- and long known as Mo¨nckeberg sclerosis.6 The precise
etiology, however, is still unclear. Emerging evidence
indicates that vascular calcification is an active cell-mediated
process that is parallel to skeletal mineralization.6 Advanced
age, long time dialysis treatment, and diabetes are main risk
factors.7 Several mechanisms are believed to contribute to
this burden: the chronic inflammatory state,8 the deranged
mineral metabolism, in particular elevated phosphate
levels,9,10 as well as the widely used calcium-based phosphate
binders.11 Recent Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines recommend plain X-rays for an
assessment of vascular calcification.12 Radiographs are
universally available, cheap, and easy to perform. Vascular
calcification has been shown to be associated with cardio-
vascular events in dialysis patients.13–15 However, these
studies were all carried out in long-term prevalent dialysis
populations, which makes those studies susceptible to
survival or onset-confounding bias. We therefore investigated
vascular calcifications in an inception cohort of dialysis
patients using plain X-rays of pelvis and calves.
One further aspect is allowed for in this paper: almost half
of our patients underwent kidney transplantation during
follow-up. For statistical analysis, however, this is associated
with substantial bias, as health status and cardiovascular risk
of patients undergoing renal transplantation (RTX) substan-
tially differ from those remaining on dialysis.16 Instead of
censoring (or non-censoring) of observation period of
patients undergoing RTX, we used a time-dependent
covariate to account for this kind of difference.
RESULTS
At the start of dialysis therapy, 104 out of 154 patients
(67.5%) showed radiologically visible calcifications. During
the observation period of on average 66746 months, 46
patients (29.9%) suffered a cardiovascular event as listed in
Table 1. Thirteen of these 46 patients suffered a further
cardiovascular event during the further observation period.
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However, only the first event was considered for the analysis.
Seventy patients underwent kidney transplantation, and two
of them underwent two transplantations. From the 83
patients who died, 41% of these deaths were of cardiovascular
reasons (myocardial infarction, heart failure, sudden death
and ischemic as well as hemorrhagic stroke) and 59% of non-
cardiovascular reasons (mainly infections and therapy with-
drawals and other reasons).
Univariate analysis
Univariate comparison of baseline characteristics between
patients with and without cardiovascular events during
follow-up is provided in Table 2. Thirty-eight of the 46
patients (82.6%) who suffered a cardiovascular event during
follow-up showed vascular calcifications at baseline com-
pared to 61.1% of patients without an event (P¼ 0.009).
Similarly, the frequency of a history of previous cardiovas-
cular events before the start of dialysis treatment was
significantly higher (23.9 vs 9.3%, P¼ 0.015). The composite
variable ‘vascular risk score’ defined by these two variables
showed the most pronounced differences between the two
groups (P¼ 0.004). Other significant variables in univariate
analysis included diabetes (P¼ 0.027) and ever-smoking
(P¼ 0.031).
The unadjusted Cox regression analysis revealed that all
three variables – the presence of vascular calcifications, the
history of a previous cardiovascular event, and each step in
the combined vascular risk score – were associated with a
more than threefold risk for a cardiovascular event during
follow-up (first part of Table 3). Kaplan–Meier survival
curves demonstrated significant differences in cumulative
event-free survival between patients with and without
previous cardiovascular events (Figure 1a), with and without
vascular calcifications at the time of enrollment (Figure 1b),
and the three groups of the vascular risk score (Figure 1c).
The latter suggests that the survival probability decreased
linearly from those patients who had neither calcifications
nor a positive cardiovascular history to those having one of
both conditions to those having both conditions at baseline
(Po0.0001; log-rank overall test).
Adjusted Cox regression analysis
Finally, the adjusted Cox regression analysis found the
vascular risk score to have the strongest association with
cardiovascular events besides age, smoking and diabetes
mellitus (additive model in Table 3). The hazard ratio of
about two indicates a twofold risk increase in case of the
presence of either vascular calcifications or a positive history
of cardiovascular events before the start of dialysis treatment
Table 1 | Number and type of the first cardiovascular events
experienced by the study participants during follow-up
Cardiovascular events n %
Myocardial infarction 15 9.7
Coronary artery bypass graft or percutaneous
transluminal angioplasty
8 5.2
Coronary stenosis 450% 10 6.5
Ischemic stroke 9 5.8
Transient ischemic attack 3 2.0
Endarterectomy or occlusion of a carotid vessel 1 0.7
Total 46 29.9
Table 2 | Univariate comparison of patients with and without cardiovascular events during follow-up
Cardiovascular events
No (n=108) Yes (n=46) P-value
Age (years) 54.8713.3 58.7712.5 0.09
Sex (females/males) 50/58 19/27 0.57
CAPD (%) 31.5 26.1 0.50
Diabetes (%) 16.7 32.6 0.027
Hypertension (%) 61.6 60 0.87
Vascular calcifications (%) 61.1 82.6 0.009
Previous cardiovascular events (%) 9.3 23.9 0.015
Vascular risk score (%) (0/1/2)a 38.0/53.7/8.3 13.0/67.4/19.6 0.004
Ever-smoking (%) 25.9 43.5 0.031
Total cholesterol (mg/dl) 224758 233755 0.41
LDL cholesterol (mg/dl) 144748 146742 0.80
HDL cholesterol (mg/dl) 41.9713.1 46.3718.7 0.11
Lipoprotein(a) (mg/dl)b 21.9723.6 29.2733.6 0.24
[4.8;11.1;33.2] [8.7;15.5;35.9]
Phosphorus time-averagedc (mmol/l) 2.0270.46 2.1470.64 0.22
Calciumphosphorus product time-averagedc (mmol2/l2) 4.5271.04 4.6671.48 0.53
Intact PTHb (ng/l) 2827252 3117307 0.64
[100;209;367] [120;234;394]
CAPD, continuous ambulatory peritoneal dialysis; HDL, high-density cholesterol; LDL, low-density cholesterol; PTH, parathyroid hormone.
aThe presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis treatment was used to
build a ‘vascular risk score’. If a patient had none of both conditions, the score was 0, in case of one of both conditions, the score was 1, and in case of both conditions, this
score was 2.
bValue is provided as mean7s.d. [25/50/75 percentile] as the variable is non-normally distributed. Comparison was made by the Mann–Whitney U-test.
cTime-averaged levels from the first year of dialysis treatment.
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and a hazard ratio of about four if both conditions were
present in comparison to patients free of both. Alternative
modeling without using this vascular risk score showed that
each of these two conditions on its own was associated with a
twofold increased risk with borderline significance (data not
shown). Furthermore, we included an interaction term
between vascular calcifications and a positive history of
cardiovascular events before the start of dialysis treatment
into the model that turned out to be not significant (see
interaction model in Table 3). This makes an effect
modification unlikely and favors an additive effect of the
two variables, which is considered in the vascular risk score of
the additive model.
DISCUSSION
Vascular calcification and cardiovascular events
This study demonstrates a strong and independent associa-
tion of the vascular risk score (constructed by the presence of
vascular calcifications and a history of cardiovascular events
before dialysis enrollment) with future cardiovascular events.
We investigated an inception cohort of dialysis patients
during a mean follow-up period of 66 months. Especially the
presence of both conditions was associated with a fourfold
increased risk.
Our study clearly demonstrates that vascular calcifications
are already present in more than two-thirds of the patients
when renal replacement therapy is started. This is in line with
a recent study in diabetic patients who demonstrated that
these vascular changes develop already in earlier stages of
chronic renal failure17 and progress rapidly during dialysis
treatment. Our results extend these findings to patients with
other causes of kidney disease and furthermore underline
vascular calcifications as an informative marker for future
cardiovascular events, especially when present in patients
with a history of a cardiovascular event.
A few other studies up to now addressed vascular
calcifications assessed with plain radiographs in end-stage
renal disease (ESRD) patients and its association with
outcome. Blacher et al.13 studied 110 long-term hemodialysis
patients and used a combination of plain radiographs and
vascular ultrasound to assess both intimal and medial
vascular calcification in four vascular regions. An increase
of one step in the four-grade score was associated with more
than threefold higher cardiovascular mortality. The same
research group14 distinguished medial from intimal calcifica-
tions by the means of plain X-rays in 202 long-term
hemodialysis patients. The authors were even able to prove
the contribution of medial calcification to all-cause and
cardiovascular mortality, albeit it was noted that outcome
was worst for patients with a mixed pattern of calcification.
Adragao et al.15 noted similar results in a group of 123
hemodialysis patients.
In our inception cohort of dialysis patients, we were not
able to find such strong correlations based on vascular
calcifications alone. This might be explained by the fact that
all of the above-mentioned studies followed prevalent cohorts
of dialysis patients undergoing maintenance dialysis for a
long time (average 81, 89, and 47 months) and that vascular
Table 3 | Association of different variables on cardiovascular events using Cox’s proportional hazards regression models
Variable Coefficient s.e.m. Wald v2 HR (95% CI) P-value
Unadjusted Cox regression
Age (year) 0.056 0.014 16.19 1.058 (1.029–1.087) o0.001
Sex (0=female, 1=male) 0.074 0.300 0.060 1.076 (0.598–1.937) 0.806
Diabetes mellitus (0=no, 1=yes) 0.911 0.320 8.117 2.486 (1.329–4.650) 0.004
Ever-smoking (0=no, 1=yes) 0.615 0.299 4.232 1.851 (1.029–3.327) 0.040
Vascular calcification (0=no, 1=yes) 1.174 0.393 8.920 3.235 (1.497–6.991) 0.003
Previous cardiovascular events (0=no, 1=yes) 1.264 0.354 12.73 3.539 (1.768–7.086) o0.001
Vascular risk score (one step)a 1.104 0.250 19.44 3.016 (1.846–4.926) o0.0001
ESRD treatment modality (time-dependent) (0=transplantation, 1=hemodialysis) 0.818 0.416 3.867 2.266 (1.003–5.121) 0.049
Adjusted Cox regression: additive model
Vascular risk score (one step)a 0.707 0.273 6.693 2.027 (1.187–3.463) 0.009
Age (year) 0.038 0.015 6.135 1.039 (1.008–1.071) 0.013
Ever-smoking (0=no, 1=yes) 0.644 0.301 4.581 1.905 (1.056–3.437) 0.032
Diabetes mellitus (0=no, 1=yes) 0.670 0.325 4.243 1.954 (1.033–3.695) 0.040
Variables not in the equation: ESRD treatment modality (time-dependent) (P=0.56), sex (P=0.35)
Adjusted Cox regression: interaction model
Age (year) 0.045 0.015 8.860 1.046 (1.015–1.077) 0.003
Diabetes mellitus (0=no, 1=yes) 0.774 0.323 5.734 2.169 (1.151–4.089) 0.017
Ever-smoking (0=no, 1=yes) 0.651 0.302 4.657 1.917 (1.062–3.462) 0.031
Previous cardiovascular events (0=no, 1=yes) 0.772 0.369 4.376 2.163 (1.050–4.458) 0.037
Variables not in the equation: vascular calcification (P=0.10), interaction term ‘previous cardiovascular event vascular calcification’ (P=0.44), ESRD
treatment modality (time-dependent) (P=0.61)
CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio, s.e.m., standard error of mean.
aThe presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis treatment was used to build a
‘vascular risk score’. If a patient had none of both the score was zero, in case of one of both conditions the score was 1, in case of both conditions this score was 2.
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calcifications are strongly associated with time already on
dialysis treatment.18 Further bias in prevalence studies can
render interpretation of data difficult:19 on the one hand, the
patients with the highest comorbidity are the most likely to
decease during the first years of treatment. On the other
hand, the healthiest patients are more likely to undergo
kidney transplantation. Therefore, prevalence studies with a
long dialysis pretreatment are very likely to involve a highly
selected patient population. Further, quite similarly, a bias
may result as a consequence of onset-confounding.19 Owing
to the difference in dialysis pretreatment between patients,
vascular calcification certainly is very heterogeneous. This
might have led to an overestimation of the effect of vascular
calcifications in earlier studies.
Recently, the results of a vascular calcification study in
patients with renal transplantation became available.20 Only
24.4% of incident transplanted patients showed vascular
calcification on a posteroanterior plain radiography of the
aortoiliacal region at the time of transplantation. This is in
contrast to a frequency of more than 60% in our incident
dialysis cohort which can be explained by the higher age of
our patients (59 vs 43 years) and the selection of healthier
patients suitable for transplantation in the above study.20
Nevertheless, the authors demonstrated that even in this
younger and healthier population, plain films can be a useful
tool to predict cardiovascular and all-cause deaths.20
Limitations of the study
The observer-dependency is a general limitation of plain
radiographs, which we tried to minimize by the fact that the
scoring in all of our patients was performed by a single
radiologist within a few days. A repeated scoring of the
radiographs from a subsample of 20 patients several months
later resulted in a 100% reproducibility. A further limitation
is that the detection sensitivity yields only semi-quantitative
data as discussed recently.21 We classified calcifications as
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Figure 1 | Cardiovascular disease during observation period. (a) Kaplan–Meier curves of cardiovascular event-free survival in patients with
and without previous cardiovascular events before the enrollment into the study, (b) with and without vascular calcifications at the time of
enrollment, and (c) the three groups of the vascular risk score (VRS). The VRS was built by summing the presence (coded as 1) or absence
(coded as 0) of vascular calcifications and of previous cardiovascular events. If a patient had none of both conditions, the score was 0, in case of
one of both conditions, the score was 1, and in case of both conditions, this score was 2. Numbers near the survival curves represent the
number of patients at risk within each stratum at the times 0, 24, 48, 72, 96, 120, and 144 months of observation.
546 Kidney International (2006) 70, 543–548
o r i g i n a l a r t i c l e JP Schwaiger et al.: Prediction score for cardiovascular events
absent or present, independent of location or extent. This
makes us unable to discriminate between minor forms vs
extensive calcifications. Unfortunately, diagnostic alternatives
with similar cost and handling are not available. Certainly,
new imaging methods such as Electron Beam Computer
Tomography (EBCT) or newer forms of spiral computed
tomography18,22,23 have promised more sensitive measure-
ments of tissue calcification, but have their own disadvan-
tages, like high costs or higher exposure to radiation.24–26
Finally, it will be necessary to validate the association of
the vascular risk score with cardiovascular outcome in an
independent study population. As our study group included
only Caucasian patients, a replication study in other
ethnicities will have to be performed.
Conclusion
Recent KDOQI guidelines recommended plain X-rays for the
assessment of vascular calcification in ESRD patients. In this
study, we were able to demonstrate a clinically highly
interesting association of a vascular risk score with cardio-
vascular outcomes in an inception cohort of dialysis patients
with a long-term follow-up.
MATERIALS AND METHODS
Patients
We enrolled 155 Caucasian dialysis patients in an Austrian dialysis
center (Feldkirch) for an investigation of vascular calcifications.27
Enrollment started in 1990 and ended by the middle of 1997. Two
patients were already recruited before 1990 as part of a pilot project.
To be included into the analysis of the data, a patient had to survive
dialysis for at least 3 months. A complete follow-up for 154 patients
is available until April 2004. Baseline characteristics are given in
Table 4.
Radiological procedures
Standardized plain radiographs from the pelvis and calves were
carried out in all patients at the start of dialysis therapy as described
recently.27 The prevalence of vascular calcifications was assessed by a
single radiologist blinded to the clinical and laboratory data.
Calcifications were counted as present if in any of these vessels either
plaque-like (patchy) and/or circumferential contiguous calcifica-
tions were noted. For investigation of the intraobserver coefficient of
variation, radiographs of 20 patients were reevaluated at least half a
year following the first evaluation. All of these samples were
correctly reclassified.
Risk factor evaluation
Diagnosis of hypertension and diabetes were based on several
measurements of blood pressure and fasting blood glucose
according to standard guidelines at the time of enrollment, or
established treatment with antihypertensive and antidiabetic drugs.
A full medical history was available for all patients. Smoking history
(ever vs never) and previous cardiovascular events were self-
reported or evaluated in the medical records. Previous cardiovas-
cular events included a history of myocardial infarction, coronary
artery bypass graft, percutaneous transluminal angioplasty, coronary
stenosis 450%, and ischemic stroke. The presence (coded as 1) or
absence (coded as 0) of vascular calcifications and for previous
cardiovascular events before the start of dialysis therapy was used to
build a ‘vascular risk score’. If a patient had none of both conditions,
the score was 0, in case of one of both conditions, the score was 1,
and in case of both conditions, this score was 2. The prevalence of
clinical and biochemical risk factors at the time of enrollment did
not differ when we stratified patients into three groups of dialysis
vintage (before 1993, 1993–1994, and after 1994).
Laboratory procedures
Baseline values of all measured parameters were obtained from
ethylenediaminetetraacetic acid plasma taken after a 12-h overnight
fast before dialysis. Lipoprotein(a) quantification was performed
using a double-antibody enzyme-linked immunosorbent assay as
described in detail.28 Lipids, lipoproteins, and apolipoproteins were
measured as described previously.27 Serum phosphorus levels and
the calcium-phosphorus product were determined each month
using the Hitachi 717 autoanalyzer (Roche, Mannheim, Germany).
These levels are provided as time-averaged levels from the first year
of dialysis treatment, to decrease intraindividual variability. Plasma
intact parathyroid hormone was measured using a commercially
available two-site immunoradiometric assay (Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA).
Outcomes and censoring
All patients were followed prospectively until April 2004. One
patient was lost to follow-up. The main outcome was a fatal or non-
fatal cardiovascular event following the initiation of dialysis
treatment. This included the following stringent criteria: definite
myocardial infarction, coronary artery bypass graft, percutaneous
transluminal angioplasty, stenosis of a coronary artery 450%
diagnosed by angiography, ischemic stroke, established clinical
diagnosis of a transient ischemic attack, and occlusion of a carotid
vessel or carotid endarterectomy. Only the first event during the
observation period was considered.
Table 4 | Baseline characteristics of 154 dialysis patients
included in the study
Age (years) 55.9713.1
Sex (females/males) 69/85
CAPD (%) 29.9
Previous cardiovascular events (%) 13.6
Vascular calcifications (%) 67.5
Vascular risk score (0/1/2)a (%) 30.5/57.8/11.7
Ever-smoking (%) 31.2
Hypertension (%) 61.2
Diabetes mellitus (%) 21.4
Total cholesterol (mg/dl) 227757
LDL cholesterol (mg/dl) 145746
HDL cholesterol (mg/dl) 43.2715.1
Lipoprotein(a) (mg/dl)b 24.1727
[6.3;12.3;34.4]
Phosphorus time-averagedc (mmol/l) 2.0670.52
Calciumphosphorus product time-averagedc (mmol2/l2) 4.5671.18
Intact PTHb (ng/l) 2867269
[114;210;375]
CAPD, continuous ambulatory peritoneal dialysis; HDL, high-density cholesterol;
LDL, low-density cholesterol; PTH, parathyroid hormone.
aThe presence (coded as 1) or absence (coded as 0) of vascular calcifications and for
previous cardiovascular events before the start of dialysis treatment was used to
build a ‘vascular risk score’. If a patient had none of both conditions, the score was 0,
in case of one of both conditions, the score was 1, and in case of both conditions,
this score was 2.
bMean7s.d. [25/50/75 percentile] as the variable is non-normally distributed.
cTime-averaged monthly levels from the first year of dialysis treatment.
Kidney International (2006) 70, 543–548 547
JP Schwaiger et al.: Prediction score for cardiovascular events o r i g i n a l a r t i c l e
Statistical procedures
Comparisons of continuous variables between patients with and
without events during follow-up were performed using the unpaired
t-test or the non-parametric Mann–Whitney U-test in case of non-
normally distributed variables. Categorical variables were compared
using Pearson’s w2 test or Fisher’s exact test. Kaplan–Meier survival
curves were used to describe the cumulative incidence of
cardiovascular event-free survival over time and the log-rank test
was used to test for differences among the investigated groups.
Unadjusted and adjusted Cox proportional hazards models were
used to identify baseline risk factors for future cardiovascular events.
The measure of association was the hazards ratio accompanied by
the corresponding 95% confidence interval. A stepwise variable
selection procedure included all variables at Po0.10 and excluded
those at P40.15. The observation period of patients undergoing
renal transplantation was not censored, but the treatment modality
entered into the adjusted Cox regression model as a time-dependent
covariate. Renal replacement modality, at a given time, was coded
and entered in the models as either 0 or 1 (functioning transplant or
dialysis, respectively).29 This method even allows to model repeated
kidney transplantations during the observation period without
censoring. In case the graft lasted less than 90 days, transplantation
was ignored in this time-dependent covariate. Death from a non-
cardiovascular event was considered as a censoring event. Variables
entered into the adjusted Cox regression hazards models were those
with a P-value o0.20 in the unadjusted Cox regression analysis as
well as the time-dependent variable ‘ESRD treatment modality’ and
sex. The analyses were carried out with SPSS for Windows (version
12.0.1) and SAS for Windows (version 9.1.3).
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